Crucial Dates for Capricor Therapeutics Shareholders
The Gross Law Firm has released an important notice for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm encourages anyone who purchased shares during the specified class period to connect with them regarding possible lead plaintiff appointments. Being appointed as the lead plaintiff isn't necessary to be part of any potential recovery.
Class Period and What It Means
CLASS PERIOD: The class period is defined from October 9, 2024, to July 10, 2025. If you acquired shares during this timeframe, your eligibility for this class action may depend on your timely registration.
Understanding the Allegations
According to the complaint filed, the allegations stem from misleading statements made by the defendants concerning Capricor's leading cell therapy candidate, deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The firm's legal papers argue that while investors were reassured about the potential for a Biologics License Application (BLA) approval from the U.S. Food and Drug Administration (FDA), vital information pertaining to the safety and efficacy from the Phase 2 HOPE-2 trial was concealed.
The Impact of Recent News
On July 11, 2025, Capricor shocked investors by stating they received a Complete Response Letter (CRL) from the FDA. This letter explicitly noted that the application did not fulfill the statutory requirements for substantial evidence of effectiveness and indicated the need for further clinical data. Following this announcement, the stock price witnessed a significant decline, dropping from $11.40 to $7.64 per share.
Registration Deadline for Investors
DEADLINE: Shareholders are reminded that the deadline to register for this class action is September 15, 2025. It’s crucial for individuals to act swiftly and make sure they are registered to be considered for recovery.
Benefits of Registering
By registering as a shareholder during the specified dates, you will gain access to portfolio monitoring services that keep you updated throughout the legal process. It’s worth noting that there is no financial obligation to participate in this case.
Understanding the Legal Firm's Role
WHY THE GROSS LAW FIRM? The Gross Law Firm is highly regarded in the realm of class action lawsuits. They advocate diligently for investors' rights who have faced financial repercussions due to fraud and deceitful practices. Their mission is to hold companies accountable and ensure they uphold ethical standards in their operations. The firm offers a compassionate approach towards those affected by misleading statements and strives to secure financial recovery for them.
Contact Information
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for this lawsuit?
The class period runs from October 9, 2024, to July 10, 2025.
What is the deadline for shareholders to register?
The registration deadline is September 15, 2025.
What should I do if I purchased Capricor shares during the class period?
Contact the Gross Law Firm to discuss your eligibility and potential recovery.
What allegations are being made against Capricor Therapeutics?
The allegations involve misleading statements regarding their lead cell therapy candidate and concealment of critical safety and efficacy data.
Why should I consider consulting the Gross Law Firm?
They have a strong track record in class action lawsuits and are dedicated to protecting investors' rights and interests.
